Abstract
Summarize available information regarding clinical impact of citalopram on the QTc interval. A literature search was conducted in Pubmed, EMBASE, and Cochrane databases using the MeSH term "long QT syndrome" and key word "citalopram" on July 11, 2014. Thirty-one studies were evaluated with 4 included in this review. Studies were excluded if they reported acute overdoses of citalopram or did not report on patient-specific risk factors for long QT syndrome (eg, hypokalemia, bradycardia, and increased age). The majority of the available data is derived from case reports. A number of confounders complicate the determination of a causal link between QTc prolongation and citalopram. Of the 4 studies included for review, none identified significant QTc prolongation in patients taking citalopram 20 to 60 mg daily without the patients having one or more patient-specific risk factors for prolonged QTc. There is insufficient evidence to establish a causal link between citalopram 20 to 60 mg orally daily and increased risk of TdP. Further research is required to determine the clinical impact and association between citalopram 20 to 60 mg daily and QTc prolongation.
References
Jul 1, 1990·The Journal of General Physiology·M C Sanguinetti, N K Jurkiewicz
Feb 1, 1997·Journal of Clinical Psychopharmacology·B BakerM J Irvine
Nov 3, 1998·Pflügers Archiv : European journal of physiology·J C HancoxH J Witchel
Oct 3, 1999·Journal of Clinical Psychopharmacology·S L RasmussenP Tanghøj
Jun 8, 2001·Clinical Neuropharmacology·G CatalanoP E Tsambiras
Feb 20, 2002·FEBS Letters·Harry J WitchelJules C Hancox
Jul 16, 2003·Medicine·David ZeltserSami Viskin
Aug 7, 2003·The Journal of Emergency Medicine·Kristin M EngebretsenJames E Wood
Sep 26, 2003·Therapeutic Drug Monitoring·Yves Le Bloc'hPierre Baumann
Aug 24, 2004·Naunyn-Schmiedeberg's Archives of Pharmacology·Edgar ZitronChristoph A Karle
Mar 8, 2005·Trends in Pharmacological Sciences·Michael C Sanguinetti, John S Mitcheson
Sep 13, 2006·British Journal of Pharmacology·S RajamaniC T January
Mar 8, 2008·Expert Opinion on Drug Safety·Serge Sicouri, Charles Antzelevitch
Jun 24, 2008·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Asim F TarabarLewis Nelson
Jan 15, 2009·Journal of Clinical Psychopharmacology·Charlotte van NoordBruno H C Stricker
Jun 23, 2009·International Journal of Cardiology·Cesare de GregorioGiuseppe Oreto
Dec 3, 2009·Praxis·M BruggisserM Bodmer
Feb 27, 2010·Journal of the American College of Cardiology·Barbara J DrewUNKNOWN American College of Cardiology Foundation
Oct 14, 2011·Pharmacopsychiatry·S UntereckerB Pfuhlmann
Jul 4, 2012·The American Journal of Medicine·W Victor R ViewegAnanda K Pandurangi
Dec 19, 2013·The Journal of Clinical Psychiatry·Ingrid M M van HaelstToine C G Egberts
Jun 13, 2014·The Journal of Clinical Psychiatry·Scott R BeachJeff C Huffman
Jan 27, 2015·Psychosomatics·Rajesh R TampiJacquelyn May
Feb 6, 2017·Anesthesia and Analgesia·Brent GerlachPaloma Toledo
Citations
Nov 29, 2017·The AAPS Journal·Nikunjkumar PatelSebastian Polak
Dec 21, 2019·The Mental Health Clinician·Megan Ehret
Jul 28, 2016·Clinical Pharmacology in Drug Development·Isaac NgDavid J Greenblatt
Apr 15, 2020·Current Psychiatry Reports·Oliver M GlassAnn C Schwartz
Nov 25, 2020·International Clinical Psychopharmacology·David CastleNaomi A Fineberg
Sep 28, 2021·Expert Opinion on Drug Safety·Janne Kaergaard Mortensen, Grethe Andersen